Related Experiment Video
Updated: Apr 25, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Assessing strategies for heart failure with preserved ejection fraction at the outpatient clinic
Insights
Diagnosing heart failure with preserved ejection fraction (HFPEF) is challenging. Combining B-type natriuretic peptide (BNP) with tissue Doppler echocardiography (TDE) improves HFPEF diagnosis over TDE alone.
Area of Science:
- Cardiology
- Medical Diagnostics
Background:
- Heart failure with preserved ejection fraction (HFPEF) is the most prevalent form of heart failure (HF).
- Accurate diagnosis of HFPEF presents significant challenges in outpatient clinical settings.
Purpose of the Study:
- To evaluate and contrast two diagnostic strategies for HFPEF based on European Society of Cardiology (ESC) guidelines.
- To assess the utility of B-type natriuretic peptide (BNP) in conjunction with echocardiographic parameters for HFPEF diagnosis.
Main Methods:
- A cross-sectional study involving 166 ambulatory patients.
- Strategy 1 (S1) utilized tissue Doppler echocardiography (TDE) and electrocardiography (ECG).
- Strategy 2 (S2) incorporated BNP measurements alongside TDE and ECG criteria.
Main Results:
- S1 confirmed HFPEF in 29% of patients using TDE and ECG criteria.
- S2, incorporating BNP, identified an additional 8% of HFPEF cases compared to S1.
- The combination of BNP and TDE demonstrated superior diagnostic yield for HFPEF.
Conclusions:
- The combined use of BNP measurement and TDE data offers a more effective diagnostic approach for HFPEF than isolated parameters.
- BNP measurement is valuable for identifying HFPEF cases missed by TDE alone, particularly in challenging outpatient scenarios.
Background:
Heart failure with preserved ejection fraction (HFPEF) is the most common form of heart failure (HF), its diagnosis being a challenge to the outpatient clinic practice.
Objective:
To describe and compare two strategies derived from algorithms of the European Society of Cardiology Diastology Guidelines for the diagnosis of HFPEF.
Methods:
Cross-sectional study with 166 consecutive ambulatory patients (67.9±11.7 years; 72% of women). The strategies to confirm HFPEF were established according to the European Society of Cardiology Diastology Guidelines criteria. In strategy 1 (S1), tissue Doppler echocardiography (TDE) and electrocardiography (ECG) were used; in strategy 2 (S2), B-type natriuretic peptide (BNP) measurement was included.
Results:
In S1, patients were divided into groups based on the E/E'ratio as follows: GI, E/E'> 15 (n = 16; 9%); GII, E/E'8 to 15 (n = 79; 48%); and GIII, E/E'< 8 (n = 71; 43%). HFPEF was confirmed in GI and excluded in GIII. In GII, TDE [left atrial volume index (LAVI) ≥ 40 mL/m2; left ventricular mass index LVMI) > 122 for women and > 149 g/m2 for men] and ECG (atrial fibrillation) parameters were assessed, confirming HFPEF in 33 more patients, adding up to 49 (29%). In S2, patients were divided into three groups based on BNP levels. GI (BNP > 200 pg/mL) consisted of 12 patients, HFPEF being confirmed in all of them. GII (BNP ranging from 100 to 200 pg/mL) consisted of 20 patients with LAVI > 29 mL/m2, or LVMI ≥ 96 g/m2 for women or ≥ 116 g/m2 for men, or E/E'≥ 8 or atrial fibrillation on ECG, and the diagnosis of HFPEF was confirmed in 15. GIII (BNP < 100 pg/mL) consisted of 134 patients, 26 of whom had the diagnosis of HFPEF confirmed when GII parameters were used. Measuring BNP levels in S2 identified 4 more patients (8%) with HFPEF as compared with those identified in S1.
Conclusion:
The association of BNP measurement and TDE data is better than the isolated use of those parameters. BNP can be useful in identifying patients whose diagnosis of HF had been previously excluded based only on TDE findings.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VI: Nursing Management

